Envoy Medical (COCH) Stock Price, News & Analysis

Envoy Medical, Inc. (NASDAQ: COCH) is a hearing health company in the surgical and medical instrument manufacturing industry. According to its public disclosures, the company is focused on providing medical technologies across the hearing loss spectrum, with a particular emphasis on fully implanted hearing devices designed to improve access, usability, compliance, independence, and quality of life for people with hearing loss.

Envoy Medical reports a single operating segment focused on hearing. Based on its filings and news releases, revenue in this segment is derived from the sale of the Esteem® fully implanted active middle ear implant (FI-AMEI) and replacement components for that system. The Esteem FI-AMEI is described as the only FDA-approved, fully implanted hearing device for adults diagnosed with moderate to severe sensorineural hearing loss that allows for 24/7 hearing capability using the ear’s natural anatomy. The device is implanted entirely under the skin, requires no externally worn components to function, and does not place anything in the ear canal. Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.

In addition to its commercial Esteem FI-AMEI system, Envoy Medical is developing the fully implanted Acclaim® cochlear implant, an investigational device that is the subject of a U.S.-based pivotal clinical trial. Company materials state that the Acclaim cochlear implant received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019. Envoy Medical describes the Acclaim cochlear implant as a first-of-its-kind, fully implanted cochlear implant designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids, and expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.

Envoy Medical’s fully implanted technology for the Acclaim cochlear implant incorporates a proprietary implanted piezoelectric sensor designed to leverage the natural anatomy of the ear instead of an external microphone to capture sound. The company’s disclosures explain that, unlike traditional, partially implanted cochlear implants, the fully implanted Acclaim cochlear implant is engineered to operate without external wearable components. Company descriptions emphasize that the Acclaim device does not use an implanted magnet to attach external components to the side of the patient’s head, and that there are no external wearable components required to hear with the Acclaim device.

Envoy Medical also highlights certain design aspects of the Acclaim cochlear implant platform in its news releases and patent-related communications. These include the use of a removable, rechargeable battery pack located in the chest that can be replaced without explanting the full system, and a design that allows several days between required battery recharging, described in one release as approximately four to five days between recharges. The company has also announced patents covering cochlear implant systems with improved input signal-to-noise ratio, where an input sensor signal is immediately amplified to generate a robust analog input signal, and systems that combine an implantable subsystem with rechargeable energy storage and a removable earplug sensor that can receive power from the implanted subsystem.

Envoy Medical’s public statements repeatedly describe its role in pioneering fully implanted hearing technologies. The company notes that it has developed two fully implanted hearing technologies: the Esteem FI-AMEI, which it states has been commercially available in the United States since 2010, and the fully implanted Acclaim cochlear implant, which remains investigational. Company communications further state that Envoy Medical is the only company to have gotten a fully implanted active hearing device through the FDA approval process to date, referring to the Esteem FI-AMEI, and that it has received Breakthrough Device Designation for its fully implanted investigational cochlear implant.

Envoy Medical is based in White Bear Lake, Minnesota, as reflected in its SEC filings, and its Class A common stock and publicly traded warrants are listed on The Nasdaq Capital Market under the symbols “COCH” and “COCHW,” respectively. The company identifies itself in SEC filings as an emerging growth company and a smaller reporting company. Its filings and news releases also emphasize an expanding intellectual property portfolio, including multiple U.S. and foreign patents related to fully implanted hearing devices, cochlear implant stimulation calibration, and systems featuring removable sensors and implanted batteries.

According to its own descriptions, Envoy Medical is dedicated to pushing hearing technology beyond the status quo, with a focus on improving access, usability, compliance, and quality of life for adults with sensorineural hearing loss. Its business model, as described in its public disclosures, combines commercial sales of the Esteem FI-AMEI and associated components with ongoing clinical development and regulatory activities for the investigational Acclaim cochlear implant, supported by capital raising activities and intellectual property development documented in its SEC filings.

Business focus and product portfolio

Envoy Medical’s primary business focus is on fully implanted hearing devices. The company’s disclosures consistently reference two core technologies:

• Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI) – a fully implanted active middle ear implant for adults with moderate to severe sensorineural hearing loss. It is described as invisible, with no externally worn components and nothing placed in the ear canal for it to function. The Esteem FI-AMEI is presented as allowing 24/7 hearing capability using the ear’s natural anatomy, and as the only FDA-approved, fully implanted hearing device of its type for this patient group.
• Acclaim® Fully Implanted Cochlear Implant (Acclaim CI) – an investigational, fully implanted cochlear implant designed to address severe to profound sensorineural hearing loss not adequately addressed by hearing aids. The Acclaim CI uses a sensor designed to leverage the natural ear rather than an external microphone to capture sound. It has received FDA Breakthrough Device Designation and is being evaluated in a pivotal clinical trial in the United States.

Envoy Medical’s public communications also describe design choices that distinguish its fully implanted cochlear implant approach from other cochlear implant systems, including the absence of an external sound processor, the use of a sensor that is fundamentally different from a subdermal microphone, and a replaceable rechargeable battery located in the chest rather than a non-replaceable rechargeable battery in the head.

Clinical development and regulatory status

The company’s news releases describe a pivotal clinical trial for the investigational fully implanted Acclaim cochlear implant. Envoy Medical has announced milestones such as six-month follow-up completion for the first cohort of patients, FDA approval to expand the pivotal trial to its final stage, enrollment of the first patients in that final stage, and subsequent enrollment progress. Company statements report that no serious adverse events were observed in certain early activation cohorts, while emphasizing that detailed hearing results cannot be disclosed until trial completion.

Envoy Medical’s disclosures repeatedly note that the fully implanted Acclaim cochlear implant is an investigational device and is limited by federal law to investigational use. They also state that the Acclaim cochlear implant received Breakthrough Device Designation from the FDA in 2019. The Esteem FI-AMEI, by contrast, is described as FDA-approved and commercially available in the United States, with important safety information provided through the company’s own channels referenced in its releases.

Capital markets and corporate structure

Envoy Medical’s SEC filings document its status as a publicly traded company with Class A common stock listed on The Nasdaq Capital Market under the symbol COCH and redeemable warrants listed under COCHW. The company has filed registration statements on Form S-1 related to offerings of Class A common stock and pre-funded warrants, as well as resale registration statements for shares underlying private placement warrants. These filings describe the company as an emerging growth company and a smaller reporting company under SEC rules.

Envoy Medical has also reported various capital raising transactions through registered direct offerings and concurrent private placements of warrants, as well as related engagement arrangements with placement agents. In addition, the company has disclosed Nasdaq listing matters, including a positive determination from a Nasdaq Hearings Panel granting additional time to demonstrate compliance with certain listing requirements and a notice regarding the minimum bid price requirement, while noting that such notices did not have an immediate effect on the continued listing of its common stock.

Intellectual property and technology development

Company news releases describe an expanding intellectual property portfolio focused on fully implanted hearing devices and cochlear implant systems. Envoy Medical has announced the grant of its 40th active U.S. patent, along with additional foreign patents, and specific patents covering cochlear implant stimulation calibration, cochlear implant systems with improved input signal-to-noise ratio, and combination implant systems featuring removable earplug sensors and implanted batteries. These patents are presented by the company as supporting its cochlear implant platform and providing protection for current and potential future device configurations and accessories.

Envoy Medical’s own statements emphasize that it has invested significant capital and time over multiple decades to reach its current position, and that it has pioneered two fully implanted hearing technologies. The company’s disclosures indicate that it intends to continue investing in its technology and product pipeline, with a focus on fully implanted hearing solutions.

Risk and regulatory considerations

Envoy Medical’s press releases and SEC filings include forward-looking statements and cautionary language regarding clinical, regulatory, market, and capital risks. These communications highlight uncertainties related to the timing and outcome of the pivotal clinical trial for the Acclaim cochlear implant, the ability to raise sufficient capital to complete that trial, compliance with Nasdaq listing requirements, potential market acceptance of the Acclaim cochlear implant if approved, and other factors that could affect future operations. Investors reviewing COCH stock are therefore directed, through the company’s own disclosures, to consider these risks alongside the company’s focus on fully implanted hearing technologies.